Nephrogen

Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies.

Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.